Next Generation Diabetes Therapy and Drug Delivery Market by Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, and Artificial Pancreas), Demographic [Adult Population (>14 years) & Child Population (<14 years)], Indication (Type 1 Diabetes & Type 2 Diabetes), and End Users (Diagnostics/Clinics, ICUs, and Home Healthcare) - Global Opportunity Analysis and Industry Forecast, 2014-2023

Next Generation Diabetes Therapy and Drug Delivery Market by Product Type (Inhalable Insulin, Oral Insulin, Insulin Patches, CGM Systems, and Artifici

Category : Medical Devices
Published On : April  2017
Pages : 140

request-discount


TOLL FREE
+1-971-202-1575
------------ Or -------------
help@researchbeam.com

Next generation diabetic therapy and drug delivery systems are used to improve the adherence to insulin in diabetic patients to reduce the risk of complications related to sudden change in the blood sugar level. Oral & inhalable insulin painlessly manage the blood glucose level, and is expected to replace the injectable insulins. The use of advanced diabetic systems, such as insulin patches, CGM systems, and artificial pancreas is expected to maintain adherence to medication in diabetic patients and improve the quality of life of diabetic patients. The global next generation diabetes therapy and drug delivery market was valued at $617 million in 2015, and is estimated to reach $9,673 million by 2023, registering a CAGR of 41.1% from 2016 to 2023.

The global next generation diabetes therapy and drug delivery market is segmented based on product type, demographic, indication, end user, and geography. Based on product type, it is classified into inhalable insulin, oral insulin, insulin patches, continuous glucose monitoring (CGM) systems, and artificial pancreas. Based on demographics, it is bifurcated into adult population (>14 years) and child population (≤14 years). Based on indication, it is divided into type 1 diabetes and type 2 diabetes. Based on end users, it is categorized into diagnostic/clinic, ICU, and home healthcare. Geographically, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

The market growth is attributed to the rise in the number of diabetic patients globally and the increase in disposable income among these patients. The benefits of using these advanced devices over conventional products, such as painless mode of insulin delivery and improvement in adherence to medication, and rise in the healthcare expenditure are expected to increase the demand for these products, thus fueling the market growth. However, lack of awareness, cost restrains in the developing regions, and less variability in products are expected to hamper the growth.

KEY MARKET BENEFITS

  • This report offers a detailed quantitative analysis of the current market trends from 2014 to 2023 to identify the prevailing opportunities.
  • The market estimations provided in this report are based on comprehensive analysis of the key developments in the industry.
  • The global market is comprehensively analyzed with respect to product type, demographic, indication, end user, and geography.
  • In-depth analysis based on geography facilitates in analyzing the regional market to assist in strategic business planning.
  • The development strategies adopted by key manufacturers are enlisted in the report to understand the competitive scenario of the market.

KEY PLAYERS PROFILED

  • Johnson & Johnson
  • Abbott Laboratories
  • Medtronic, Inc.
  • Sanofi
  • Novo Nordisk
  • MannKind Corporation
  • Enteris BioPharma
  • Dexcom, Inc.
  • Senseonics Holding, Inc.
  • Medtech

KEY MARKET SEGMENTS

By Product Type

  • Inhalable Insulin
  • Oral Insulin
  • Insulin Patches
  • CGM Systems
  • Artificial Pancreas

By Demographic

  • Adult Population (>14years)
  • Child Population (≤14years)
  • By Indication
  • Type 1 Diabetes
  • Type 2 Diabetes

By End User

  • Diagnostics/Clinics
  • ICUs
  • Home Healthcare

By Geography

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • France
    • Spain
    • Italy
    • Rest of Europe
  • Asia-Pacific
    • Japan
    • China
    • Australia
    • India
    • South Korea
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • Republic of South Africa
    • Saudi Arabia
    • Rest of LAMEA

The other players of the catheters market include (companies not profiled in the report):

  • Synertech
  • Zosano Pharma Corp.
  • Relmada Therapeutics, Inc.
  • Eli Lilly and Company
  • Transdermal Specialties Inc.

CHAPTER 1 INTRODUCTION

1.1. REPORT DESCRIPTION
1.2. KEY BENEFITS
1.3. KEY MARKET SEGMENTS
1.4. RESEARCH METHODOLOGY

1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models

CHAPTER 2 EXECUTIVE SUMMARY

2.1.1. CXO perspective

CHAPTER 3 MARKET OVERVIEW

3.1. KEY BENEFITS

3.1.1. Top investment pockets
3.1.2. Top winning strategies

3.2. PATENT ANALYSIS

3.2.1. Patent analysis by year
3.2.2. Patent analysis by region
3.2.3. Patent analysis by product type

3.3. GOVERNMENT REGULATIONS AND REIMBURSEMENT POLICIES
3.4. INNOVATIONS IN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET

3.4.1. Smart contact lenses for glucose monitoring
3.4.2. SmartGuard GlucoSitter
3.4.3. iLet Bihormonal bionic pancreas
3.4.4. Glucose nanosensors
3.4.5. Engineering beta-cell replacement therapy
3.4.6. Glucose-responsive insulin-producing cells

3.5. MARKET DYNAMICS

3.5.1. Drivers

3.5.1.1. Rise in incidence of diabetes along with increase in disposable income
3.5.1.2. Rise in healthcare expenditure
3.5.1.3. Benefits of using next generation diabetic products over conventional products

3.5.2. Restaints

3.5.2.1. Cost restrains
3.5.2.2. Lack of awareness
3.5.2.3. Less variability in products

3.5.3. Opportunities

3.5.3.1. Developing products with fewer side effects at affordable costs
3.5.3.2. High undiagnosed diabetic patient population
3.5.3.3. Tapping potential in developing regions

CHAPTER 4 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT TYPE

4.1. OVERVIEW

4.1.1. Market size and forecast

4.2. INHALABLE INSULIN

4.2.1. Key market trends
4.2.2. Key growth factors and opportunities
4.2.3. Market size and forecast

4.3. ORAL INSULIN

4.3.1. Key market trends
4.3.2. Key growth factors and opportunities
4.3.3. Market size and forecast

4.4. INSULIN PATCHES

4.4.1. Key market trends
4.4.2. Key growth factors and opportunities
4.4.3. Market size and forecast

4.5. CGMS

4.5.1. Key market trends
4.5.2. Key growth factors and opportunities
4.5.3. Market size and forecast

4.6. ARTIFICIAL PANCREAS

4.6.1. Key market trends
4.6.2. Key growth factors and opportunities
4.6.3. Market size and forecast

CHAPTER 5 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS

5.1. OVERVIEW

5.1.1. Market size and forecast

5.2. ADULT POPULATION (>14YEARS)

5.2.1. Market size and forecast

5.3. CHILD POPULATION (14YEARS)

5.3.1. Market size and forecast

CHAPTER 6 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATIONS

6.1. OVERVIEW
6.2. TYPE I DIABETES

6.2.1. Market size and forecast

6.3. TYPE II DIABETES

6.3.1. Market size and forecast

CHAPTER 7 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USERS

7.1. OVERVIEW

7.1.1. Market size and forecast

7.2. DIAGNOSTICS/CLINICS

7.2.1. Market size and forecast

7.3. ICUS

7.3.1. Market size and forecast

7.4. HOME HEALTHCARE

7.4.1. Market size and forecast

CHAPTER 8 NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY

8.1. NORTH AMERICA

8.1.1. Key market trends
8.1.2. Key growth factors and opportunities
8.1.3. Market size and forecast

8.2. EUROPE

8.2.1. Key market trends
8.2.2. Key growth factors and opportunities
8.2.3. Market size and forecast

8.3. ASIA-PACIFIC

8.3.1. Key market trends
8.3.2. Key growth factors and opportunities
8.3.3. Market size and forecast

8.4. LAMEA

8.4.1. Key market trends
8.4.2. Key growth factors and opportunities
8.4.3. Market size and forecast

CHAPTER 9 COMPANY PROFILES

9.1 ABBOTT LABORATORIES

9.1.1 Company Overview
9.1.2 Operating Business Segment Overview
9.1.3 Financial performance
9.1.4 Strategic moves and developments
9.1.5 Key strategic moves & developments

9.2 DEXCOM, INC.

9.2.1 Company overview
9.2.2 Operating Business Segment Overview
9.2.3 Business performance
9.2.4 Key Strategies and development
9.2.5 Key strategic moves & developments

9.3 ENTERIS BIOPHARMA

9.3.1 Overview
9.3.2 Operating Business Segment Overview
9.3.3 Financial performance
9.3.4 Strategic moves and developments
9.3.5 Key strategic moves & developments

9.4 JOHNSON & JOHNSON

9.4.1 Company overview
9.4.2 Operating Business Segment Overview
9.4.3 Business performance
9.4.4 Strategic moves and developments
9.4.5 Key strategic moves & developments

9.5 MANNKIND CORPORATION

9.5.1 Company overview
9.5.2 Operating Business Segment Overview
9.5.3 Business performance
9.5.4 Strategic moves and developments
9.5.5 Key strategic moves & developments

9.6 MEDTECH

9.6.1 Company overview
9.6.2 Operating Business Segment Overview
9.6.3 Business performance
9.6.4 Strategic moves and developments
9.6.5 Key strategic moves & developments

9.7 MEDTRONIC, INC.

9.7.1 Company overview
9.7.2 Operating Business Segment Overview
9.7.3 Business Performance
9.7.4 Strategic moves and developments
9.7.5 Key strategic moves & developments

9.8 NOVO NORDISK

9.8.1 Company overview
9.8.2 Operating Business Segment Overview
9.8.3 Financial performance
9.8.4 Strategic moves and developments
9.8.5 Key strategic moves & developments

9.9 SANOFI

9.9.1 Company overview
9.9.2 Operating Business Segment Overview
9.9.3 Financial performance
9.9.4 Strategic moves and developments
9.9.5 Key strategic moves & developments

9.10 SENSEONICS HOLDING, INC.

9.10.1 Company overview
9.10.2 Operating Business Segment Overview
9.10.3 Financial performance
9.10.4 Strategic moves and developments
9.10.5 Key strategic moves & developments

LIST OF TABLES

TABLE 1. RISE IN INCIDENCE OF DIABETES IN DIFFERENT GEOGRAPHIC REGIONS FROM 2015 TO 2040 (MILLION)
TABLE 2. RISE IN HEALTHCARE EXPENDITURE IN DIFFERENT GEOGRAPHIC REGIONS FROM 2015 TO 2040 ($BILLION)
TABLE 3. UNDIAGNOSED DIABETIC PATIENT POPULATION IN DIFFERENT GEOGRAPHIC REGIONS IN 2015 (MILLION)
TABLE 4. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2014-2023 ($MILLION)
TABLE 5. INHALABLE INSULIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 6. ORAL INSULIN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 7. INSULIN PATCH NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 8. CGM SYSTEMS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 9. ARTIFICIAL PANCREAS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 10. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS, 2014-2023 ($MILLION)
TABLE 11. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR ADULT POPULATION, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 12. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET FOR CHILD POPULATION, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 13. NEXT GENERATION TYPE I DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 14. NEXT GENERATION TYPE II DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 15. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USERS, 2014-2023 ($MILLION)
TABLE 16. DIAGNOSTICS/CLINICS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 17. ICUS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 18. DIAGNOSTICS/CLINICS NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 19. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY GEOGRAPHY, 2014-2023 ($MILLION)
TABLE 20. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2014-2023 ($MILLION)
TABLE 21. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS, 2014-2023 ($MILLION)
TABLE 22. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2014-2023 ($MILLION)
TABLE 23. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USERS, 2014-2023 ($MILLION)
TABLE 24. NORTH AMERICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2014-2023 ($MILLION)
TABLE 25. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2014-2023 ($MILLION)
TABLE 26. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS, 2014-2023 ($MILLION)
TABLE 27. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2014-2023 ($MILLION)
TABLE 28. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USERS, 2014-2023 ($MILLION)
TABLE 29. EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2014-2023 ($MILLION)
TABLE 30. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2014-2023 ($MILLION)
TABLE 31. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS, 2014-2023 ($MILLION)
TABLE 32. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2014-2023 ($MILLION)
TABLE 33. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USERS, 2014-2023 ($MILLION)
TABLE 34. ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2014-2023 ($MILLION)
TABLE 35. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY PRODUCT TYPE, 2014-2023 ($MILLION)
TABLE 36. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY DEMOGRAPHICS, 2014-2023 ($MILLION)
TABLE 37. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY INDICATION, 2014-2023 ($MILLION)
TABLE 38. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY END USERS, 2014-2023 ($MILLION)
TABLE 39. LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, BY COUNTRY, 2014-2023 ($MILLION)
TABLE 40. COMPANY SNAPSHOT
TABLE 41. ABBOTT LABORATORIES: COMPANY SNAPSHOT
TABLE 42. DEXCOM, INC.: COMPANY SNAPSHOT
TABLE 43. ENTERIS BIOPHARMA: COMPANY SNAPSHOT
TABLE 44. JOHNSON & JOHNSON: COMPANY SNAPSHOT
TABLE 45. MANNKIND CORPORATION: COMPANY SNAPSHOT
TABLE 46. MEDTECH: COMPANY SNAPSHOT
TABLE 47. MEDTRONIC, INC.: COMPANY SNAPSHOT
TABLE 48. NOVO NORDISK: COMPANY SNAPSHOT
TABLE 49. SANOFI: COMPANY SNAPSHOT
TABLE 50. SENSEONICS HOLDING, INC.: COMPANY SNAPSHOT

LIST OF FIGURES

FIGURE 1. GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET: SEGMENTATION
FIGURE 2. TOP INVESTMENT POCKETS: GLOBAL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY, BY END USERS
FIGURE 3. TOP WINNING STRATEGIES: PERCENTAGE DISTRIBUTION (2014-2016)
FIGURE 4. PATENT REGISTERED/APPROVED- BY YEAR
FIGURE 5. PATENT REGISTERED/APPROVED- BY REGION
FIGURE 6. PATENT REGISTERED/APPROVED- BY PRODUCT TYPE
FIGURE 7. U.S. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 8. CANADA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 9. MEXICO NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 10. GERMANY NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 11. FRANCE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 12. U.K. NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 13. REST OF EUROPE NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 14. JAPAN NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 15. CHINA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 16. AUSTRALIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 17. INDIA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 18. REST OF ASIA-PACIFIC NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 19. BRAZIL NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 20. REPUBLIC OF SOUTH AFRICA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 21. REST OF LAMEA NEXT GENERATION DIABETES THERAPY AND DRUG DELIVERY MARKET, 2014-2023 ($MILLION)
FIGURE 22. ABBOTT LABORATORIES: REVENUE, 2014-2016 ($MILLION)
FIGURE 23. ABBOTT LABORATORIES: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 24. ABBOTT LABORATORIES: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 25. DEXCOM, INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 26. DEXCOM, INC.: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 27. DEXCOM, INC.: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 28. ENTERIS BIOPHARMA: REVENUE, 2014-2016 ($MILLION)
FIGURE 29. ENTERIS BIOPHARMA: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 30. ENTERIS BIOPHARMA: REVENUE SHARE BY GEOGRAPHY, 2016 (%)
FIGURE 31. JOHNSON & JOHNSON: REVENUE, 2014-2016 ($MILLION)
FIGURE 32. JOHNSON & JOHNSON: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 33. JOHNSON & JOHNSON: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 34. JOHNSON & JOHNSON: STRATEGY SHARE, 2014-2016 (%)
FIGURE 35. MANNKIND CORPORATION: REVENUE, 2014-2016 ($MILLION)
FIGURE 36. MANNKIND CORPORATION: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 37. MANNKIND CORPORATION: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 38. MANNKIND CORPORATION: STRATEGY SHARE, 2014-2016 (%)
FIGURE 39. MEDTECH: REVENUE, 2014-2016 ($MILLION)
FIGURE 40. MEDTECH: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 41. MEDTECH: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 42. MEDTRONIC, INC.: REVENUE, 2014-2016 ($MILLION)
FIGURE 43. MEDTRONIC, INC.: REVENUE SHARE BY SEGMENT, 2016 (%)
FIGURE 44. MEDTRONIC, INC.: REVENUE SHARE, BY GEOGRAPHY, 2016 (%)
FIGURE 45. NOVO NORDISK: REVENUE, 2013-2015 ($MILLION)
FIGURE 46. NOVO NORDISK: REVENUE SHARE BY SEGMENT, 2015 (%)
FIGURE 47. NOVO NORDISK: REVENUE SHARE, BY GEOGRAPHY, 2015 (%)
FIGURE 48. NOVO NORDISK: STRATEGY SHARE, 2014-2016 (%)
FIGURE 49. SANOFI: REVENUE, 2013-2015 ($MILLION)
FIGURE 50. SANOFI: STRATEGY SHARE, 2014-2016 (%)
FIGURE 51. SENSEONICS HOLDING, INC.: REVENUE, 2013-2015 ($MILLION)
FIGURE 52. SENSEONICS HOLDING, INC.: STRATEGY SHARE, 2014-2016 (%)

Enquiry Before Buy